U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

ACTIV CLINICAL TRIALS FINDER

Find possible COVID-19 clinical trials for your patient.

Answer key questions to learn about options for your patients to join a clinical trial that is evaluating new treatments for COVID-19. Select the options that best match your patient’s condition to narrow down the available trials (found below the finder ACTIV Clinical Trials Finder). Note: specific inclusion criteria may not reflect the most current study protocol.

Click on the "Find" button to see the updated list of possible clinical trials for your patient.

*Having a weakened immune system (also known as being "immunocompromised") means that a person’s white bloods cells are less effective at fighting disease. Many illnesses can cause a weakened immune system, including chronic (long-term) conditions like diabetes and cancer; infections, like HIV; and some autoimmune diseases like lupus or rheumatoid arthritis. Sometimes, medications a person is taking may cause the immune system to weaken. These may include medications related to chemotherapy, systemic steroids, methotrexate, and others.

**Symptoms may include one or more of the following:

  • fever
  • cough
  • fatigue
  • diarrhea
  • sore throat
  • body pains and aches
  • headache, chills
  • nausea/vomiting
  • difficulty breathing/shortness of breath/dyspnea
  • new loss of sense of taste or smell
  • nasal symptoms/congestion/discharge

ACTIV clinical trial options for your patient

Your patient may qualify for the clinical trial(s) listed below.

The eligibility criteria is time-sensitive.

Please encourage your patient to contact the trial(s) as soon as possible to learn more about how to participate. Each trial has its own direct contact information.

OTAC: Outpatient Treatment with Anti-Coronavirus Immunoglobulin (immunocompromise)

What treatment is being tested in this trial?
COVID-19 disease is caused by infection with the SARS-CoV-2 virus. Anti-SARS-CoV-2 hyperimmune intravenous immunoglobulin (hIVIG) is made by combining and concentrating antibodies from different healthy people who have recovered from COVID-19. The anti-SARS-CoV-2 antibodies bind to the virus and keep it from entering into cells. It is also different from “convalescent plasma” from a single person in that hIVIG consistently provides a high level of antibodies. In the lab it has been shown to work better against “variant” (i.e., “mutated” or changed) forms of the SARS-CoV-2 virus than single or combination antibody treatments. Variant forms of the virus have become widespread in different parts of the world.

What is the type of clinical trial being conducted?
Randomized, double-blind, placebo-controlled trial. Participants will have a 50-50 chance (like tossing a coin) of being assigned to the “active” study drug, hIVIG, or placebo (salt water with no study drug).

About this trial:
People early on in their infection who test positive for COVID-19 and have a higher risk of getting very sick will take part in this study. The study team hopes to find out if giving anti-SARS-CoV-2 hIVIG to people early in their infection with COVID-19, before the body has had a chance to make its own antibodies, can help prevent bad effects from COVID-19 and enable them to stay out of the hospital. If you join this study you will receive either the study drug, hIVIG, or placebo given through a vein in the arm as a single dose. You will also get the usual treatment and care for COVID-19 according to local guidelines. The study lasts 28 days with some of the scheduled study visits taking place over the phone.

For more information:
Call: 877-414-7243 Email: [email protected] Chat now

ACTIV-4 Host Tissue: Novel Experimental COVID Therapies Affecting Host Response (NECTAR)

What drugs are being tested in this trial?
Several different new drugs are being studied to help people in the hospital with COVID-19. Each drug is different and may be given in a different way. This can include by IV, mouth, or injection.

What is the type of clinical trial being conducted?
This is a randomized, double-blind, placebo-controlled trial.

About this trial:
You may be able to join the NECTAR study if you have tested positive for COVID-19 and are in the hospital. If you join the study, you will either receive a study drug or something that looks like the study drug but has no medicine in it called a placebo.

The chance of receiving either a study drug or the placebo depends on the number of study drugs available when you join the study. You will not know if you are receiving the study drug or the placebo. Both groups are important to the study to help find out if getting the new drugs are better than not getting them.

You will be in this study for 90 days. You do not need to be in the hospital this entire time. You will receive the study treatment for up to 14 days, depending on which drug you are assigned.

For more information:
Call: 615-875-8531 Email: vcc.ne[email protected] Learn more Chat now

OTAC: Outpatient Treatment with Anti-Coronavirus Immunoglobulin

What treatment is being tested in this trial?
COVID-19 disease is caused by infection with the SARS-CoV-2 virus. Anti-SARS-CoV-2 hyperimmune intravenous immunoglobulin (hIVIG) is made by combining and concentrating antibodies from different healthy people who have recovered from COVID-19. The anti-SARS-CoV-2 antibodies bind to the virus and keep it from entering into cells. It is also different from “convalescent plasma” from a single person in that hIVIG consistently provides a high level of antibodies. In the lab it has been shown to work better against “variant” (i.e., “mutated” or changed) forms of the SARS-CoV-2 virus than single or combination antibody treatments. Variant forms of the virus have become widespread in different parts of the world.

What is the type of clinical trial being conducted?
Randomized, double-blind, placebo-controlled trial. Participants will have a 50-50 chance (like tossing a coin) of being assigned to the “active” study drug, hIVIG, or placebo (salt water with no study drug).

About this trial:
People early on in their infection who test positive for COVID-19 and have a higher risk of getting very sick will take part in this study. The study team hopes to find out if giving anti-SARS-CoV-2 hIVIG to people early in their infection with COVID-19, before the body has had a chance to make its own antibodies, can help prevent bad effects from COVID-19 and enable them to stay out of the hospital. If you join this study you will receive either the study drug, hIVIG, or placebo given through a vein in the arm as a single dose. You will also get the usual treatment and care for COVID-19 according to local guidelines. The study lasts 28 days with some of the scheduled study visits taking place over the phone.

For more information:
Call: 877-414-7243 Email: [email protected] Chat now

ACTIV-3b: THERAPEUTICS FOR SEVERELY ILL INPATIENTS WITH COVID-19 (TESICO): Determining which treatments help hospitalized adults with acute respiratory distress due to COVID-19 get better

What drugs are being tested in this trial?
Aviptadil and remdesivir (additional drugs may be added later).

What is the type of clinical trial being conducted?
Randomized, double-blind, placebo-controlled trial.

About this trial:
This trial is enrolling adult patients being treated in the hospital for COVID-19 who are experiencing acute respiratory failure, a condition in which patients are critically ill and have difficulty breathing. This study will assess if aviptadil and remdesivir together or alone are safe and help patients recover more quickly from COVID-19.

Aviptadil is a man-made version of a hormone (Vasoactive Intestinal Peptide or VIP) found naturally in the body, which may decrease COVID-19 virus levels, inflammation, and help protect the lungs. Remdesivir (Veklury®) is an antiviral drug that may decrease COVID-19 virus levels and lung injury. It is approved as a treatment for people in the hospital with COVID-19 but it is not known if it will help people with serious COVID-19 illness who need very high levels of oxygen or a ventilator. Both study drugs are given by intravenous (IV) infusion.

In general, patients will have a 3 in 4 chance of receiving one or both of the study drugs. (Depending on the specifics of their medical situation, some patients may only be randomized to one drug or its placebo, in which case they would have a 1 in 2 chance of receiving the study drug.) Other study drugs may be added to the trial in the future. Drug treatments that show little effectiveness will be dropped from the trial and other therapies can be added.

For more information:
Call: 877-414-7243 Email: [email protected] Chat now

ACTIV-3 THERAPEUTICS FOR INPATIENTS WITH COVID-19 (TICO): A multicenter, adaptive, randomized, blinded controlled trial of the safety and efficacy of investigational therapeutics for hospitalized patients with COVID-19

The number of study drugs available will determine the chance that a study participant receives a study drug rather than placebo. If a participant is able to receive either of the study drugs, their chance of getting a study drug is 67 percent (2 in 3).

What drugs are being tested in this trial?

  1. AZD7442 monoclonal antibodies. Monoclonal antibodies are laboratory-made versions of proteins naturally produced by the body’s immune system to fight infections. AZD7442 has two monoclonal antibodies that were identified from people who recovered from COVID-19. Each of these monoclonal antibodies attaches to a different part of SARS-CoV-2 to try to stop it from multiplying in the body and help people recover from COVID-19.
  2. MP0420 DARPin. A DARPin is a protein that is made in a laboratory. MP0420 attaches to three different parts of SARS-CoV-2 to try to stop it from multiplying in the body and help people recover from COVID-19.
  3. Additional drugs may be added later.

What type of clinical trial is being conducted?
A randomized, double-blind, placebo-controlled, adaptive platform trial.

Randomized means that whether trial participants get one of the study drugs or the placebo is decided by chance – like flipping a coin. Placebo-controlled means that some participants will receive a saltwater solution that has no drug in it. Trial participants will always have a 50 percent (50:50) chance or greater of getting a study drug. Double-blind means that neither the participant nor the research team will know if a participant is getting a study drug or the placebo. Adaptive platform means the trial has study drugs entering and leaving based on specific study requirements. This allows quick and careful assessments of study drugs to identify those that are safe and effective in treating people in the hospital with COVID-19.

About this trial:
ACTIV-3/TICO is enrolling adults being treated in the hospital for COVID-19 and will examine how well study drugs compare with placebo in helping them to recover. It will determine if the study treatments are safe to use and help people go home from the hospital more quickly and stay home. Everyone in this study will also receive study-provided remdesivir (Veklury®), the only FDA-licensed treatment for patients in the hospital. Remdesivir is an antiviral drug that may decrease levels of the virus that causes COVID-19 (SARS-CoV-2) in the body. Another treatment often used for patients in the hospital with COVID-19 is dexamethasone, a steroid that helps people with COVID-19 who require oxygen or other respiratory support.

For more information:
Call: 877-414-7243 Email: [email protected] Chat now

ACTIV-2: Determining which investigational medications can help adults with COVID-19 get better

What drugs are being tested in this trial?
Multiple different medicines against COVID-19.

What is the type of clinical trial being conducted?
Randomized, double-blind, placebo-controlled trial.

About this trial:
The ACTIV-2 study is testing different investigational medicines to see if they are safe and can help adults with COVID-19 get better. The investigational medicines that researchers believe are most likely to help people with COVID-19 will be tested in this study. One type of investigational medicine you might receive in the study is a monoclonal antibody. Antibodies are naturally made by your body to help fight disease. Monoclonal antibodies are made in the laboratory and help your body attack invaders, such as viruses, to keep them from entering your cells. Promising medicines other than monoclonal antibodies are also being tested in this study. If you decide to join you would be given information about the medicines currently being tested.

For more information:
Call: 877-414-6404 Visit riseabovecovid.org Chat now

ACTIV-5: Big Effects Trial (BET)

What investigational drugs are being tested in this study?
Several investigational drugs.

What type of clinical trial is being conducted?
Randomized, double-blind, placebo-controlled trials.

About this trial:
ACTIV-5 compares different types of drugs (immune modulators, antivirals, and others) against a common placebo patients in the hospital with COVID-19. It is enrolling a smaller number of participants to detect which treatments have a big effect on patient outcomes and should be moved quickly into larger studies. Drug treatments that show little effectiveness will be dropped from the trial to allow other therapies to be added.

For more information:
Call: 301-761-7948 Email: [email protected] Chat now

ACTIV-4: (ACTIV-4C) Determining how effective blood thinners are in reducing blood clots in adults diagnosed with COVID-19

What treatments are being tested in this trial?
Blood thinners.

What is the type of clinical trial being conducted?
Randomized, open-label study.

About this trial:
ACTIV-4 is assessing the safety and effectiveness of different kinds of blood thinners to treat adults diagnosed with COVID-19. Many patients who died from COVID-19 had formed blood clots throughout their bodies, including in their smallest blood vessels. This unusual clotting problem has caused multiple health complications from organ damage to heart attack, stroke, and blockage in arteries in the lungs. ACTIV-4 trials aim to prevent and treat life-threatening COVID-19-associated blood clotting.

ACTIV-4C for patients who are recovering after hospital discharge:
This clinical trial is assessing the effectiveness and safety of blood thinning drugs in reducing complications from blood clots such as heart attack, stroke, blood clots in major veins and arteries, blood clots in veins deep in the body and/or in arteries in the lungs, and death in patients who have been discharged from the hospital and are recovering. Participants will be assigned to take either a low dose of the blood thinner apixaban (Eliquis®) or placebo.

For more information:
Chat now

ACTIV-4: (ACTIV-4A) Determining how effective blood thinners are in reducing blood clots in adults diagnosed with COVID-19

What treatments are being tested in this trial?
Antithrombotics (blood thinners).

What is the type of clinical trial being conducted?
Randomized, open-label study.

About this trial:
ACTIV-4 is assessing the safety and effectiveness of different kinds of blood thinners to treat adults diagnosed with COVID-19. Many patients who died from COVID-19 had formed blood clots throughout their bodies, including in their smallest blood vessels. This unusual clotting problem has caused multiple health complications from organ damage to heart attack, stroke, and blockage in arteries in the lungs. ACTIV-4 trials aim to prevent and treat life-threatening COVID-19-associated blood clotting.

ACTIV-4A for patients in the hospital:
This clinical trial for patients who are in the hospital with COVID-19 is assessing the safety and effectiveness of different doses and types of heparin, a blood thinner, to prevent or reduce the formation of blood clots. This treatment may be given with remdesivir (Veklury®), an FDA-approved antiviral for patients in the hospital that reduces the ability of viruses to multiply in the body.

For more information:
Chat now

ACTIV-1

What treatments are being tested in this trial?
Immune modulators and remdesivir.

What is the type of clinical trial being conducted?
Randomized, double-blind, placebo-controlled trial.

About this trial:
This trial is enrolling adult patients who are already in the hospital with moderate to serious COVID-19 disease. The trial is testing promising drugs that modulate, or adjust, the immune system to help reduce the harmful effects that can occur when the immune response to a COVID-19 infection is too strong. These drugs are called immune modulators. In this trial doctors assess the safety and effectiveness of three immune modulators taken with an antiviral called remdesivir (Veklury®), which has already been approved by the FDA for use in patients in the hospital. Antivirals like remdesivir reduce the ability of viruses to multiply in the body. Doctors will study the different treatments to see how well they reduce the severity of the illness and speed recovery.

For more information:
Call: 877-384-6573 Learn more Chat now

ACTIV-6: Determining which repurposed medicines can help adults with COVID-19 get better

What drugs are being tested in this trial?
Multiple different FDA-approved medicines repurposed against COVID-19.

What is the type of clinical trial being conducted?
Randomized (like a flip of a coin), double-blind (you and your doctor will not know which medicine you’re taking), placebo-controlled trial (a treatment that has none of the active drug in it).

About this trial:
The ACTIV-6 study is testing medicines that are currently used for treating health conditions other than COVID-19 to see if these medicines can be used for treating COVID-19. The main goal is to find out if these medicines can help people with mild to moderate COVID-19 feel better faster and stay out of the hospital. Before you decide if you want to join the study you will know what medicines are being tested. If you join you will receive the usual treatment for your condition plus any study treatment as part of the ACTIV-6 trial. This study is designed to be done remotely so it can fit into your life easily. The ACTIV-6 study is currently for people who are at least 30 years old, have been diagnosed with COVID-19 and have symptoms, and who are not currently in the hospital.

For more information:
Call: 1-833-385-1880 Chat now Learn more
*This page was updated: December 2, 2021